 2. Patients who are refractory to, relapsed after or intolerant to standard therapy, or for whom no standard therapy exists: i Advanced thyroid carcinoma -- Anaplastic thyroid carcinoma: Positive IHC for V600E or known history of BRAF mutation is allowed to enroll; Locoregional disease no longer amenable to curative surgery or radiation, or advanced disease with measurable primary or metastatic disease; Papillary thyroid carcinoma -- Must be beyond 3 weeks from last radioactive iodine treatment and AEs associated with previous therapy must be resolved to Grade 1 or baseline; Thyroid stimulating hormone TSH less than the upper limit of normal ULN per institutional laboratory ranges. ii Other advanced tumors eg. colorectal cancer, non-small cell lung cancer, cholangiocarcinoma. 